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Abstract	Proton	 magnetic	 resonance	 spectroscopy	 measurements	 of	 glutamate	 and	 GABA	 are	important	 in	 neuropsychiatric	 research.	 Some	 study	 designs	 require	 simultaneous	measurement	 of	 both	 metabolites.	 GABA	 measurement	 requires	 specialized	 pulse	sequences,	 the	 most	 common	 approach	 being	 J-difference	 spectral	 editing	 with	 MEGA-PRESS.	This	method	enables	two	different	strategies	for	concurrently	measuring	glutamate	-	from	either	off-resonance	or	difference	spectra.	However,	neither	strategy	has	previously	been	 compared	 directly	 to	 conventional	 glutamate	 measurements.	 Here	 we	 compared	these	 approaches	 in	 49	 subjects	 (28	 healthy	 volunteers	 and	 21	 first-episode	 psychosis	patients),	 in	whom	both	PRESS	(TE	80)	and	MEGA-PRESS	(TE	68)	spectra	were	obtained	from	 dorsolateral	 prefrontal	 cortex.	 Glutamate	 and	 glx	 estimates	 from	 MEGA-PRESS	difference	and	off-resonance	spectra	were	compared	to	glutamate	and	glx	estimates	from	PRESS	 spectra	 using	 correlational	 analyses.	 In	 healthy	 volunteers,	 correlations	 between	PRESS	and	MEGA-PRESS	off-resonance	values	were	r	≥	0.88	and	were	significantly	higher	than	correlations	between	PRESS	and	MEGA-PRESS	difference	spectrum	values	(r	≤	0.36).	Patients	showed	a	similar	pattern.	Lower	correlations	with	difference	spectrum	values	may	reflect	a	disproportionate	 impact	of	 field	 instabilities	on	co-edited	glutamate	signals.	The	results	support	substituting	MEGA-PRESS	off-resonance	spectra,	but	not	difference	spectra,	for	 separately-acquired	 PRESS	 spectra	 in	 studies	 requiring	 simultaneous	 glutamate	 and	GABA	measurements.			
Keywords:	glutamate,	GABA,	MRS,	simultaneous,	brain,	metabolites,	measurement		 	
Highlights	1.	Glutamate	can	be	measured	two	ways	during	a	GABA-optimized	MEGA-PRESS	scan.	2.	 These	 glutamate	 measurements	 have	 not	 been	 directly	 compared	 to	 conventional	methods.	3.	MEGA-PRESS	off-resonance	glutamate	values	correspond	well	to	PRESS	values.		4.	MEGA-PRESS	difference	spectra	glutamate	values	correspond	poorly	to	PRESS	values.	5.	Results	favor	off-resonance	spectra	for	measuring	glutamate	in	GABA-optimized	scans.		
	 	
1.	Introduction1		Proton	 magnetic	 resonance	 spectroscopy	 (1H-MRS)	 is	 a	 technique	 for	 the	 non-invasive	measurement	of	neurometabolites	in	defined	regions	of	the	human	brain.		Using	optimized	acquisition	 sequences,	 10	 or	 more	 different	 brain	 metabolites	 may	 be	 present	 in	sufficiently	 high	 concentration	 to	 be	 measurable	 with	 clinical	 scanners.	 Among	 these	metabolites,	 glutamate	 and	 GABA	 are	 of	 particular	 interest,	 as	 their	 functions	 include	serving	 as	 the	 principal	 excitatory	 and	 inhibitory	 neurotransmitters,	 respectively.	Disruption	 of	 glutamatergic	 and	 GABAergic	 systems	 has	 been	 implicated	 in	 a	 variety	 of	neuropsychiatric	 disorders,	 including	 psychotic	 disorders,	 seizure	 disorders,	 and	 mood	disorders	(Jun	et	al.,	2014;	Luykx	et	al.,	2012;	Maddock	and	Buonocore,	2012;	Marsman	et	al.,	2013;	Schur	et	al.,	2016;	van	Veenendaal	et	al.,	2015).		Aspects	of	brain	metabolism	or	neurotransmission	 involving	 glutamate	 and	 GABA	 may	 be	 promising	 targets	 for	 the	development	of	novel	 treatments	 for	 these	disorders	(Poels	et	al.,	2014;	Waschkies	et	al.,	2014).	 	 Thus,	 1H-MRS	 may	 have	 a	 key	 role	 in	 testing	 the	 engagement	 of	 targeted	mechanisms	 by	 such	 novel	 treatments.	 While	 many	 clinical	 investigators	 may	 wish	 to	measure	glutamate	and	GABA	simultaneously,	it	is	not	clear	at	present	whether	this	can	be	adequately	 done	 using	 a	 single	 1H-MRS	 acquisition	 sequence.	 Glutamate	 is	 most	 often	measured	 using	 conventional	 PRESS	 or	 STEAM	 sequences,	 while	 measuring	 GABA	 on	 a	clinical	scanner	requires	use	of	a	specialized	acquisition	sequence	(Wijtenburg	et	al.,	2015;	
																																								 																				1	1H-MRS:	proton	magnetic	resonance	spectroscopy;	dlPFC:	dorsolateral	prefrontal	cortex;	CoV:	 coefficient	 of	 variation:	 CRLB:	 Cramer-Rao	 lower	 bounds;	 FoV:	 field	 of	 view;	 glx:	glutamate+glutamine;	MEGA-PRESS:	Mescher-Garwood	 point-resolved	 spectroscopy;	MP-Diff:	 MEGA-PRESS	 difference	 spectrum;	 MP-Off:	 MEGA-PRESS	 off-resonance	 spectrum;	NAA:	 n-acetylaspartate;	 NAAG:	 n-acetylaspartylglutamate;	 NEX:	 number	 of	 excitations;	PRESS:	 point-resolved	 spectroscopy;	 RF:	 radio	 frequency;	 STEAM:	 stimulated	 echo	acquisition	mode;	TE:	echo	time;	TR:	repetition	time.	
Harris	et	al.,	2017),	the	most	widely	used	of	which	is	the	MEGA-PRESS	sequence	(Mescher	et	 al.,	 1998).	 MEGA-PRESS	 sequences	 used	 to	 measure	 GABA	 can	 also	 provide	 nominal	measures	of	glutamate	(Mescher	et	al.,	1998),	but	it	is	not	yet	known	to	what	extent	such	glutamate	measurements	 are	 comparable	 to	 those	 acquired	 using	 PRESS	 or	 STEAM.	 The	goal	 of	 the	 current	 study	 is	 to	 compare	 glutamate	 measurements	 obtained	 using	 a	conventional	 PRESS	 sequence	 with	 those	 acquired	 using	 a	 widely	 available,	 GABA-optimized,	MEGA-PRESS	sequence.				A	 key	 challenge	 in	 measuring	 glutamate	 is	 distinguishing	 its	 resonances	 from	 nearby	resonances	arising	from	glutamine,	GABA	and	glutathione.	When	using	conventional	pulse	sequences	at	field	strengths	below	3T,	spectral	resolution	is	not	sufficient	for	curve-fitting	algorithms	to	adequately	isolate	the	glutamate	resonances.	Under	such	conditions,	the	total	signal	near	 the	glutamate	 resonances	 is	 referred	 to	 as	 glx,	which	 indicates	 the	 combined	signal	 from	glutamate	and	some	of	 these	other	resonances,	 in	proportions	 that	vary	with	different	 scanning	 parameters	 and	 basis	 sets.	 Even	 at	 field	 strengths	 of	 3T	 or	 higher,	separation	 from	other	metabolites	 (especially	glutamine)	 is	 sometimes	a	problem	for	 the	measurement	of	glutamate	with	conventional	pulse	sequences,	and	the	degree	of	overlap	varies	with	echo	time	(Schubert	et	al.,	2004).		In	addition,	glutamate	measurement	may	be	hampered	by	overlap	with	macromolecules	at	short	echo	times	and	by	the	J-evolution	of	its	complex	multiplet	resonances	at	longer	echo	times.	In	an	effort	to	find	an	optimal	echo	time	for	 measuring	 glutamate	 at	 3T,	 one	 group	 (Schubert	 et	 al.,	 2004)	 showed	 that	 a	 PRESS	sequence	 using	 TE=	 80	 ms	 produced	 both	 a	 strong	 signal	 for	 the	 2.34	 and	 3.74	 ppm	glutamate	resonances	and	good	separation	of	 the	glutamate	resonance	at	2.34	ppm	 from	
macromolecules,	 glutamine,	 and	other	 resonances.	These	 investigators	also	 showed	good	correspondence	between	glutamate	values	obtained	with	this	method	and	those	obtained	using	 a	 specialized	 multiple	 quantum	 coherence	 filter	 sequence	 designed	 to	 isolate	glutamate.	Subsequently,	this	method	has	been	used	in	a	variety	of	clinical	 investigations,	including	 two	 independent	 studies	 demonstrating	 elevated	 hippocampal	 glutamate	 in	patients	with	schizophrenia	(Gallinat	et	al.,	2016;	Kraguljac	et	al.,	2013).		The	1H-MRS	spectrum	of	GABA	contains	three	multiplet	resonances.	When	acquired	with	conventional	acquisition	methods,	all	three	resonances	are	almost	completely	obscured	by	overlapping	 signals	 from	 more	 highly	 concentrated	 brain	 metabolites.	 Thus,	 special	acquisition	techniques	are	needed	(Wijtenburg	et	al.,	2015;	Harris	et	al.,	2017).	The	most	widely	used	method	 for	 identifying	 and	measuring	GABA	 is	 J-difference	 editing,	 typically	using	a	MEGA-PRESS	sequence	with	a	TE	of	~68	msec	(Mescher	et	al.,	1998;	Mullins	et	al.,	2014).		This	method	takes	advantage	of	the	fact	that	the	C2	methylene	resonance	of	GABA	at	3.01	ppm	is	J-coupled	to	the	C3	methylene	resonance	of	GABA	at	1.89	ppm	(Govindarju	et	 al.	 2000).	 The	 J-evolution	 associated	with	 this	 coupling	 causes	 inversion	 of	 the	 outer	triplet	peaks	of	GABA	at	3.01	ppm	at	echo	times	near	68	msec.	The	on-resonance	editing	pulse	selectively	inverts	the	resonance	at	1.89	ppm,	which	reverses	the	J-modulation	of	the	coupled	peak	at	3	ppm,	 such	 that	 the	magnetization	of	 this	 signal	 fully	 refocuses	at	echo	times	 near	 68	 msec.	 The	 GABA-optimized	 MEGA-PRESS	 sequence	 interleaves	 an	 on-resonance	 editing	 pulse	with	 an	 off-resonance	 editing	 pulse.	 In	 post-processing,	 the	 off-resonance	acquisition	is	subtracted	from	the	on-resonance	acquisition,	yielding	an	upright	GABA	resonance	at	3.0	ppm,	while	resonances	that	lack	a	coupling	partner	near	1.89	ppm	
are	 subtracted	 away	 (Mescher	 et	 al.,	 1998).	 Thus,	 the	MEGA-PRESS	 difference	 spectrum	contains	a	quantifiable	GABA	signal	that	is	relatively	isolated	from	most	other	resonances.	In	addition,	resonances	from	glutamate,	glutamine	and	glutathione	have	coupling	partners	near	2.1	ppm,	and	these	signals	often	co-edit	with	GABA.	Many	MEGA-PRESS	sequences	use	an	 editing	 pulse	 bandwidth	 that	 is	 sufficiently	 broad	 to	 at	 least	 partially	 refocus	 the	 J-evolution	of	these	2.1	ppm	coupling	partners.	When	this	is	the	case,	glutamate	resonances	at	 3.74	 and	 2.34	 ppm,	 glutamine	 resonances	 at	 3.75	 and	 2.45	 ppm,	 and	 glutathione	resonances	 at	 3.77	 and	 2.53	 ppm	 co-edit	 with	 GABA	 and	 are	 retained	 in	 the	 difference	spectrum.	 Many	 investigators	 have	 used	 co-edited	 signals	 in	 the	 difference	 spectra	 to	quantify	 glutamate	 or	 glx	 (Kegeles	 et	 al.,	 2012;	 Milak	 et	 al.,	 2016;	 Yoon	 et	 al.,	 2010).	Alternatively,	 the	off-resonance	spectrum	from	a	GABA-optimized	MEGA-PRESS	sequence	will	be	very	similar	to	a	conventional	PRESS	sequence	when	the	frequency	selectivity	of	the	off-resonance	editing	pulse	 is	outside	the	range	of	most	metabolites	(e.g.	7.5	ppm).	Many	investigators	have	used	these	off-resonance	spectra	to	measure	glutamate	(Maddock	et	al.,	2016;	Ongur	et	al.,	2011;	Stan	et	al.,	2015).	Because	of	the	similarity	to	a	PRESS	sequence,	glutamate	 measurements	 from	 the	 off-resonance	 spectra	 acquired	 with	 a	 MEGA-PRESS	sequence	should	correspond	closely	those	from	a	PRESS	sequence	acquired	with	a	similar	echo	 time.	 In	 contrast,	 the	 difference	 spectra	 from	 a	 MEGA-PRESS	 sequence	 are	 quite	different	from	PRESS	spectra.	Although	glutamate	signal	is	present	in	both	types	of	spectra,	it	is	not	easy	to	predict	how	closely	the	glutamate	values	will	correspond	between	the	two	acquisition	 strategies.	 To	 our	 knowledge,	 neither	 of	 these	 approaches	 to	 measuring	glutamate	 from	GABA-optimized	MEGA-PRESS	spectra	has	been	systematically	 compared	to	glutamate	measurements	obtained	from	a	conventional	PRESS	acquisition.	This	study	is	
designed	 to	 directly	 compare	 these	 different	 approaches	 to	 measuring	 glutamate.	 The	ability	to	measure	glutamate	and	GABA	simultaneously	is	particularly	important	when	the	time	 course	 of	 activity-dependent	 changes	 in	 these	 metabolites	 is	 the	 focus	 of	 study.	 If	glutamate	 values	 measured	 from	 a	 MEGA-PRESS	 scan	 are	 found	 to	 be	 substantially	equivalent	to	such	values	measured	from	a	conventional	PRESS	scan,	then	investigators	can	have	 confidence	 in	 glutamate	measurements	 obtained	 simultaneously	with	MEGA-PRESS	GABA	 measurements	 without	 need	 of	 adding	 a	 separate	 PRESS	 acquisition	 to	 their	experimental	protocol.		
2.	Methods	
2.1	Participants	Participants	were	 28	 healthy	 volunteers	 (24	male,	 aged	 19	 to	 37,	mean	 age	 26)	 and	 21	patients	receiving	treatment	for	first-episode	psychosis	(15	male,	aged	18	to	32,	mean	age	23),	all	of	whom	were	recruited	as	part	of	a	larger	study	of	cognition	and	brain	function	in	first-episode	psychosis.		All	participants	were	medically	and	psychiatrically	assessed	prior	to	brain	 imaging,	and	were	free	of	significant	medical	problems.	Healthy	volunteers	were	free	of	 current	 or	past	psychiatric	diagnoses.	All	 participants	provided	 informed	 consent	following	a	protocol	 approved	by	 the	 IRB	of	 the	University	of	California,	Davis	 and	were	screened	for	magnetic	resonance	imaging	contraindications.		
2.2	Magnetic	resonance	imaging	and	spectroscopy	acquisitions	MR	 data	 were	 acquired	 using	 a	 3	 Tesla	 Siemens	 TIM/trio	 scanner	 (Berlin/Munich,	Germany)	with	a	32-channel	radiofrequency	head	coil.		The	single	scanning	session	began	
with	a	T1-weighted	structural	scan	(MPRAGE,	TR/TE	=	2500/4	ms,	1100	ms	TI,	flip	angle	=	7°,	FoV	256	*	256,	0.95	mm3	voxel	size,	acceleration	factor	of	two)	that	was	used	to	guide	voxel	placement.	A	30	*	15	*	35	mm	voxel	was	centered	on	 the	 left	middle	 frontal	gyrus	(dlPFC),	with	the	voxel	orientation	rotated	to	maximize	the	amount	of	cortical	grey	matter,	while	accommodating	each	individual	participant's	anatomy.	The	outer	surface	of	the	voxel	was	positioned	a	few	millimeters	inside	the	cortical	surface	to	avoid	inclusion	of	meninges	in	 the	 measurements.	 Figure	 1	 demonstrates	 typical	 voxel	 placement.	 A	 combination	 of	advanced	automated	and	manual	voxel	shimming	was	used	to	minimize	line	width.	A	series	of	 four	 MEGA-PRESS	 subscans	 were	 then	 acquired	 from	 the	 dlPFC	 voxel.	 MEGA-PRESS	scanning	parameters	were	TR/TE	=	1500/68	ms,	edit	pulse	frequencies	=	1.9	ppm	(on)	and	7.5	ppm	(off),	Gaussian	edit	pulse	bandwidth	=	45	Hz,	delta	frequency	=	-1.7	ppm	relative	to	water	(optimized	for	signal	detection	at	3.0	ppm),	water	suppression	bandwidth	=	50	Hz,	NEX	 =	 72	 each	 for	 on-	 and	 off-resonance	 acquisitions,	 duration	 =	 3.6	min).	 Dividing	 the	acquisition	 into	 four	short	subscans	allowed	 for	a	quick	updating	and	re-centering	of	 the	water	frequency	between	scans.	This	was	intended	to	reduce	the	effects	of	frequency	offset	(drift)	on	the	editing	pulse	and	required	only	a	few	seconds.	Thus,	the	four	subscans	were	acquired	in	rapid	succession.	The	subscans	were	later	combined	off-line	for	analysis.	Total	data	acquisition	 time	 for	all	 four	MEGA-PRESS	scans	was	14.4	minutes	and	 included	288	excitations	each	for	the	on-	and	off-resonance	acquisitions.	Next,	a	single	PRESS	scan	was	acquired	from	the	same	dlPFC	voxel.	PRESS	scanning	parameters	were	TR/TE	=	1500/80	ms,	 delta	 frequency	 =−	 1.7	 ppm,	 water	 suppression	 bandwidth	 =	 50	 Hz,	 NEX	 =	 160,	duration	 =	 4.0	min.	Most	 subjects	 subsequently	 had	MEGA-PRESS,	 but	 not	 PRESS,	 scans	acquired	from	a	second	brain	region.	These	data	will	be	reported	separately.	
	
2.3	Data	processing	and	analysis	Glutamate	and	other	metabolite	signals	were	quantified	from	PRESS	spectra,	MEGA-PRESS	difference	spectra	(MP-Diff),	and	MEGA-PRESS	off-resonance	spectra	(MP-Off)	using	either	model	fitting	with	LCModel	v6.3	1-L	(Provencher,	1993)	or	a	peak	integration	procedure.			
2.3.1	Model	fitting	of	PRESS	spectra	For	 PRESS	 spectra,	metabolite	 values	were	 fit	 using	 an	 analysis	window	 from	4.0	 to	 1.7	ppm	 and	 a	 simulated	 basis	 set	 provided	 with	 LCModel	 that	 included	 the	 following	metabolites:	 glutamate,	 glutamine,	 glutathione,	 creatine,	 phosphocreatine,	 n-acetylaspartate	 (NAA),	 n-acetylaspartylglutamate	 (NAAG),	 phosphocholine,	glycerophosphorylcholine,	 myo-inositol,	 scyllo-inositol,	 aspartate,	 taurine,	 GABA,	 and	glucose.	 Glx	 for	 this	 and	 for	 all	 model	 fitting	 analyses	 in	 this	 study	 is	 defined	 as	 the	 fit	estimate	 for	glutamate	plus	the	 fit	estimate	 for	glutamine.	Glutamate	and	glx	 from	PRESS	acquisitions	were	 normalized	 to	 Creatine	 (calculated	 as	 creatine	 +	 phosphocreatine)	 for	statistical	comparisons.			
2.3.2	Model	fitting	of	MEGA-PRESS	off-resonance	spectra	and	difference	spectra	For	 both	 the	 difference	 and	 the	 off-resonance	MEGA-PRESS	 spectra,	 the	 first	 processing	step	consisted	of	phase	and	frequency	correction	of	the	averaged	data	from	each	of	the	four	3.6-minute	subscans	using	LCModel.	The	 four	aligned	spectra	were	 then	combined	 in	 the	time	domain	for	quantification	of	metabolite	values	with	LCModel.	The	basis	sets	used	for	both	 the	 difference	 and	 the	 off-resonance	 spectra	 were	 based	 on	 published	 coupling	
constants	and	chemical	shifts	(Govindaraju	et	al.	2000;	Kaiser	et	al.,	2008)	and	simulated	with	 custom	 software	 (Murdoch,	 1982).	 The	 simulations	were	designed	 for	 use	with	 the	Siemens	 MEGA-PRESS	 sequence	 and	 are	 available	 for	 download	 at:	http://purcell.healthsciences.purdue.edu/mrslab/basis_sets.html.	 For	 the	 MP-Off	 spectra,	metabolite	values	were	fit	in	LCModel	using	an	analysis	window	from	4.0	to	1.7	ppm.	The	basis	 set	 included	 glutamate,	 glutamine,	 glutathione,	 creatine,	 NAA,	 NAAG,	glycerophosphorylcholine,	myo-inositol,	scyllo-inositol,	aspartate,	taurine,	and	GABA	(Long	et	al.,	2014).	Glutamate	and	glx	from	the	MP-Off	spectra	were	normalized	to	creatine.	For	the	difference	spectra,	metabolite	values	were	fit	using	an	analysis	window	from	4.2	to	1.95	ppm,	 as	 recommended	 in	 the	 LCModel	manual.	 The	 basis	 set	 included	 GABA,	 glutamate,	glutamine,	 glutathione,	 NAA,	 and	 NAAG	 (Long	 et	 al.,	 2014).	 Glutamate	 and	 glx	 from	 the	difference	spectra	were	normalized	to	creatine	as	measured	in	the	MP-Off	spectra.			
2.3.3	Peak	integration	of	glx	in	the	MEGA-PRESS	difference	spectra	The	peak	integration	method	cannot	separate	overlapping	signals.	Thus	a	measurement	of	glutamate	alone	was	not	considered	feasible	with	peak	integration.	Our	estimate	of	glx	by	peak	integration	included	combined	signal	from	co-edited	glutamate	and	glutamine,	plus	a	small	 contribution	 from	co-edited	 glutathione.	This	was	quantified	using	 jMRUI	 software	(version	 5.2)	 (Stefan	 et	 al.,	 2009)	 and	Excel	 to	 calculate	 the	 area	 under	 the	 curve	 of	 the	pseudo-doublet	 resonance	 centered	 at	 3.74	 (±0.10)	 ppm	 in	 the	 MP-Diff	 spectra,	 as	previously	 described	 (Greenhouse	 et	 al.,	 2016;	 Yoon	 et	 al.,	 2010).	 This	 glx	 estimate	was	normalized	 to	 creatine,	 which	was	 quantified	 by	 integration	 of	 the	 peak	 at	 3.02	 (±0.09)	ppm	in	the	summed	(on-	plus	off-	resonance)	MEGA-PRESS	spectra.	
	
2.3.4	Statistical	analyses	Each	of	the	MEGA-PRESS-based	methods	for	measuring	glutamate	or	glx	were	compared	to	the	 PRESS-based	measurement	 acquired	 from	 the	 same	 voxel	 in	 each	 subject.	 Pearson’s	correlation	 (r)	 with	 the	 PRESS	 measure	 and	 the	 corresponding	 r2	 value	 (reflecting	 the	proportion	 of	 variance	 shared	by	 the	 two	 variables)	 in	 the	 sample	 of	 healthy	 volunteers	were	 considered	 the	 primary	 outcome	 measures	 for	 assessing	 similarity	 to	 the	 PRESS	values.	Statistical	significance	of	differences	between	these	r	values	was	calculated	by	the	method	of	 Steiger	 (Steiger,	 1980),	which	 is	 appropriate	when	 the	 two	 correlations	 share	one	variable	in	common	as	in	this	study	(i.e.	comparing	the	correlation	between	PRESS	and	MP-Off	values	to	the	correlation	between	PRESS	and	MP-Diff	values).	Alpha	for	significance	differences	between	correlations	was	set	at	.05,	two-tailed.			In	addition,	the	coefficient	of	variation	(CoV)	across	the	sample	of	normal	volunteers	was	calculated	 and	 compared	 for	 each	 measure	 of	 glutamate	 and	 glx.	 This	 comparison	 was	intended	 to	 provide	 an	 estimate	 of	 the	 nuisance	 variance	 (noise)	 introduced	 by	 the	measurement	strategy.	Since	the	underlying	true	sample	variance	should	be	similar	for	all	measurement	methods,	 we	 reasoned	 that	methods	 resulting	 in	 higher	 CoVs	would	 have	added	more	nuisance	variance	than	methods	associated	with	lower	CoVs.	Calculation	of	the	significance	 of	 differences	 between	 the	 CoVs	 was	 based	 on	 the	 t-distribution	 (Zaiontz,	2017).	In	addition	to	the	primary	analyses	conducted	in	the	sample	of	healthy	volunteers,	Pearson’s	r,	r2,	and	CoV	values	were	also	calculated	for	the	sample	of	patients	and	for	the	combined	sample	of	patients	and	controls.	
	Differences	 in	dlPFC	glutamate	values	between	 the	patient	 and	 control	 groups	were	also	examined.	 As	 the	 PRESS	 acquisitions	 with	 TE	 =	 80	 were	 considered	 a	 priori	 our	 best	measure	 of	 glutamate,	 these	 data	 were	 used	 in	 testing	 for	 group	 effects,	 which	 were	examined	by	analysis	of	variance	with	group	as	a	factor.	Alpha	was	set	at	.05,	two-tailed.			
3.	Results	
3.1	Quality	of	MRS	data	All	spectra	were	visually	inspected	for	significant	artifact	due	to	excess	water,	excess	lipid,	or	motion	(Ernst	and	Chang,	1996)	resulting	in	6	of	the	49	subjects	being	excluded	from	the	analysis.	Reasons	for	exclusion	were:	lipid	contamination	of	MP-Off	(2	patients)	or	PRESS	spectra	(1	control),	water	contamination	of	MP-Off	spectra	(1	patient	and	1	control),	and	excessive	 within-scan	motion	 (1	 control).	 An	 additional	 patient	 was	 excluded	 when	 her	history	of	an	old	ischemic	stroke	was	discovered.	Thus,	the	analysis	was	based	on	complete	data	 from	25	healthy	 controls	 and	17	patients.	 Spectral	 quality	 indices	 for	 included	data	were	as	follows.	Median	LCModel	estimates	of	signal-to-noise	and	full-width	half-maximum	for	PRESS	and	MP-OFF	spectra	were	36	(range	24	–	43)	and	.036	ppm	(range	.024	-	.048),	respectively.	The	corresponding	values	for	the	MP-Diff	spectra	were	23	(range	15	–	27)	and	.040	 ppm	 (range	 .028	 -	 .055).	 Cramer-Rao	 lower	 bounds	 (CRLBs)	 in	 PRESS	 and	 MP-Off	spectra	were	all	≤	7	for	glutamate	and	≤	8	for	glx.	CRLBs	in	MP-Diff	spectra	were	all	≤	7	for	glutamate	and	≤	5	for	glx.		
3.2	Correlation	analyses	
Tables	1	and	2	show	Pearson	correlations	(r)	and	r2	between	the	different	MEGA-PRESS-derived	measures	and	the	PRESS-derived	measure	of	glutamate	(Table	1)	and	glx	(Table	2).		Additional	correlations	are	shown	in	the	Supplemental	Tables.	For	both	glutamate	and	glx	in	the	healthy	volunteers,	measures	derived	from	the	MP-Off	spectra	demonstrated	strong	correlations	 and	 a	 high	 percentage	 of	 shared	 variance	 (r2	 ≥	 .77)	 with	 the	 PRESS-based	values.	In	contrast,	measures	derived	from	the	MP-Diff	spectra,	whether	by	LCModel	fits	or	by	peak	integration,	evidenced	little	shared	variance	with	the	PRESS-based	values	(all	r2	≤	.13	 in	 healthy	 volunteers).	 For	 both	 glutamate	 and	 glx	 in	 the	 sample	 of	 25	 healthy	volunteers,	the	correlations	between	MP-Off	and	PRESS	were	significantly	greater	than	the	correlations	between	MP-Diff	or	MP-Diff-PI	 and	PRESS	 (all	p	 <	 .0001).	 Similar	 significant	differences	were	observed	across	the	combined	sample	of	volunteers	and	patients	(all	p	<	.0001).	 In	 the	 smaller	 sample	 of	 patients	 alone,	 these	 differences	 were	 in	 the	 same	direction,	 and	 they	 were	 significant	 for	 glutamate	 but	 not	 for	 glx.	 Figure	 2	 shows	scatterplots	of	glutamate	and	glx	values	obtained	from	the	PRESS	spectra	versus	the	three	methods	 based	 on	 the	MEGA-PRESS-derived	 spectra	 in	 the	 combined	 sample	 of	 healthy	volunteers	and	patients.		
	
3.3	Coefficients	of	variation	The	coefficients	of	variation	for	glutamate	and	glx	values	are	shown	in	Table	1	and	Table	2,	respectively.	In	the	healthy	volunteers,	Glutamate	and	glx	CoVs	from	the	MP-Off	or	the	MP-Diff	spectra	did	not	differ	significantly	from	CoVs	from	the	PRESS	spectra.	In	the	combined	sample,	glutamate	CoV,	but	not	glx	CoV,	was	significantly	higher	in	MP-Diff	than	in	MP-Off	spectra	(z	=	2.69,	n	=	42,	p	<	.01).	
	
3.4	Group	comparisons	Analysis	of	variance	of	PRESS	glutamate/creatine	ratios	with	group	as	a	factor	showed	no	differences	between	the	patient	and	control	groups	(mean	=	.90,	s.d.	=	.07;	mean	=	.90,	s.d.	=	.08,	 respectively;	 F	 =	 0.00,	 df	 =	 1,	 40,	 NS).	 Similarly,	 no	 group	 difference	 was	 seen	 for	glx/creatine	(mean	=	.96,	s.d.	=	.09;	mean	=	.95,	s.d.	=	.11,	respectively;	F	=	0.06,	df	=	1,	40,	NS).		
4.	Discussion	
4.1	Glutamate	from	off-resonance,	but	not	difference	spectra,	corresponds	to	PRESS	
values	As	expected,	glutamate	and	glx	measurements	generated	from	the	off-resonance	spectra	of	a	GABA-optimized	MEGA-PRESS	sequence	were	highly	 correlated	with	glutamate	and	glx	measurements	derived	from	a	conventional	PRESS	scan	acquired	with	a	TE	of	80	msec.	In	contrast,	 glutamate	 and	 glx	 measurements	 generated	 from	 the	 difference	 spectra	 of	 a	GABA-optimized	MEGA-PRESS	sequence	had	 little	shared	variance	(quantified	as	r2)	with	these	 same	 measurements	 derived	 from	 a	 PRESS	 scan.	 In	 a	 sample	 of	 young	 healthy	volunteers,	 the	 difference	 in	 the	 correlations	 between	 these	 paired	 measurements	 was	highly	 significant.	 A	 similar	 pattern	 of	 results	 was	 observed	 in	 a	 smaller	 sample	 of	medicated,	 first	 episode	 psychosis	 patients,	 and	 in	 the	 larger	 sample	 combining	 both	patients	 and	 healthy	 volunteers.	 It	 is	 worth	 noting	 that	 similar	 results	 were	 observed	whether	glutamate	was	quantified	alone	or	whether	the	combined	signals	from	glutamate	and	 glutamine	 (glx)	 were	 quantified	 together.	 In	 both	 the	 control	 subjects	 and	 in	 the	
combined	 sample,	 we	 observed	 no	 significant	 differences	 in	 how	 well	 glutamate	 or	 glx	values	 from	 the	MP-Off	 or	MP-Diff	 spectra	 correlated	with	PRESS	 spectra	 values.	 To	 our	knowledge,	 this	 is	 the	 first	 study	 directly	 comparing	 glutamate	 values	 from	 PRESS	 and	MEGA-PRESS	 acquisitions.	 The	 results	 provide	 empirical	 support	 for	 using	 the	 off-resonance	spectra	rather	than	the	difference	spectra	from	a	GABA-optimized	MEGA-PRESS	sequence	as	a	proxy	for	a	conventional	PRESS	sequence.	This	strategy	may	be	particularly	useful	when	investigators	are	interested	in	obtaining	simultaneous	measurements	of	GABA	and	glutamate	from	the	same	voxel.			The	 coefficients	 of	 variation	 for	 glutamate	 and	 glx	 values	 did	 not	 differ	 significantly	between	the	PRESS	and	the	off-resonance	MEGA-PRESS	acquisitions.	However,	CoVs	were	slightly	 lower	 in	 every	 comparison	 for	 the	 latter	 (Tables	 1	 and	2).	 	 This	 apparent,	 slight	reduction	in	noise	variance	may	partly	stem	from	the	MEGA-PRESS	off-resonance	spectra	being	 acquired	 for	 a	 total	 of	 7.2	minutes	 (288	 reps,	 or	 one-half	 of	 the	 total	 14.4	minute	MEGA-PRESS	acquisition	time),	while	the	PRESS	spectra	were	acquired	for	only	4	minutes	(160	 reps).	 Since	 reliable	 GABA	 measurements	 using	 MEGA-PRESS	 require	 longer	 scan	times	than	conventional	PRESS	scans	(Brix	et	al.,	2017),	this	potential	advantage	for	the	off-resonance	glutamate	measurements	is	inherent	in	the	design	of	most	GABA	studies.	In	any	case,	 our	 results	 provide	 no	 evidence	 that	 glutamate	 or	 glx	 values	 from	 off-resonance	MEGA-PRESS	acquisitions	are	noisier	than	those	from	PRESS	acquisitions.	However,	in	the	combined	 sample,	 glutamate	 estimates	 from	 the	 MEGA-PRESS	 difference	 spectra	 had	significantly	 higher	 CoVs	 than	 glutamate	 estimates	 from	 the	 off-resonance	 spectra,	
suggesting	 the	 presence	 of	 additional	 noise	 in	 the	 difference	 spectrum	 estimates	 of	glutamate.		Our	 results	 suggest	 that	 glutamate	 estimates	 from	 PRESS	 and	 MP-Off	 spectra	 are	measuring	similar	underlying	quantities,	and	that	these	quantities	differ	from	what	is	being	measured	by	the	glutamate	estimates	from	MP-Diff	spectra.	Both	the	method	of	generating	the	spectra	and	 the	basis	sets	 for	quantifying	glutamate	 from	them	are	highly	similar	 for	the	 PRESS	 and	 the	 MP-Off	 spectra,	 and	 dissimilar	 for	 the	 MP-Diff	 spectra.	 Thus,	 it	 was	expected	 that	 PRESS	 and	 MP-Off	 spectra	 would	 provide	 similar	 measures	 of	 glutamate.	Many	 factors	may	 have	 contributed	 to	 the	 poorer	 correspondence	 between	MP-Diff	 and	PRESS	 measures	 of	 glutamate	 and	 glx.	 Editing	 parameters	 that	 are	 suboptimal	 for	glutamate	may	play	an	important	role.		The	editing	pulse	frequency	(1.9	ppm)	used	in	our	MEGA-PRESS	 editing	 sequence	 used	was	 optimized	 for	 editing	 GABA,	 but	 not	 glutamate	(for	 which	 2.1	 ppm	 is	 optimal).	 Furthermore,	 the	 GABA-optimized	 echo	 time	 may	 have	been	less	than	optimal	for	editing	the	2.34	ppm	and	3.74	ppm	resonances	of	glutamate.	In	addition,	 the	 basis	 set	 used	may	 have	 not	 been	 optimal	 for	 quantifying	 glutamate	 in	 the	difference	 spectra.	 These	 factors	 may	 have	 reduced	 the	 efficiency	 and	 increased	 the	variability	of	the	measurement	of	co-edited	glutamate	in	our	subjects,	and	thus	contributed	to	 the	dissimilarity	between	MP-Diff	 and	PRESS	values.	We	explore	 in	more	detail	below	some	of	these	possibilities.		
4.2	Possible	role	of	frequency	offset	during	the	MEGA-PRESS	acquisition	
Frequency	 offset	 in	 an	 MRS	 acquisition	 can	 result	 from	 imprecision	 in	 the	 prescan	frequency	calibration	or	from	frequency	changes	over	time	due	to	several	factors,	including	magnetic	 field	 drift	 and	 subject	motion	 during	 the	 scan.	Metabolite	measurements	 from	MEGA-PRESS	difference	spectra	can	be	particularly	vulnerable	to	the	confounding	effects	of	frequency	 offset.	 In	 the	 ideal	 implementation	 of	 our	 MEGA-PRESS	 sequence,	 the	 on-resonance	editing	pulse	will	remain	centered	at	1.9	ppm	throughout	the	entire	acquisition.	With	a	bandwidth	of	0.365	ppm	(45	Hz),	our	Gaussian	editing	pulse	has	only	an	off-center	interaction	 with	 the	 glutamate	 resonance	 at	 2.1	 ppm	 (Supplemental	 Figure).	 Frequency	offset	during	the	scan	changes	the	location	of	the	editing	pulse	in	the	frequency	domain	and	alters	its	interactions	with	the	2.1	ppm	glutamate	resonance,	thus	altering	its	efficiency	for	editing	glutamate.	 Importantly,	 the	 longer	 scan	 times	used	 for	GABA	editing	 increase	 the	likelihood	of	significant	field	drift	or	subject	motion	during	the	acquisition.	Van	der	Veen	et	al.	 (2017)	 recently	 demonstrated	 the	 effects	 of	 frequency	 offset	 on	 metabolite	 values	measured	 in	 the	 difference	 spectra	 of	 a	 GABA-optimized	MEGA-PRESS	 acquisition	 at	 3T.	Among	 their	 findings	 was	 the	 observation	 that	 the	 glutamate/creatine	 ratio	 in	 the	difference	 spectra	was	 significantly	 and	positively	 correlated	with	 the	average	downfield	frequency	offset	(i.e.	toward	higher	ppm	values)	during	the	MEGA-PRESS	scan	(r	=	0.48	and	
r	 =	 0.51	 in	 two	 frontal	 voxels).	 This	 most	 likely	 reflects	 increased	 editing	 efficiency	 for	glutamate	 caused	by	 the	downfield	 frequency	offset.	With	downfield	offset,	 the	 center	 of	the	editing	pulse	moves	closer	to	the	glutamate	coupling	partner	at	2.1	ppm	and	generates	a	larger	glutamate	signal	in	the	difference	spectrum.		
In	 light	 of	 these	 considerations,	 we	 estimated	 the	 average	 frequency	 offset	 during	 the	MEGA-PRESS	acquisition	to	see	if	 it	could	account	for	the	low	correlation	between	PRESS	and	MP-Diff	values	for	glutamate	and	glx.	We	used	the	observed	frequency	of	the	creatine	peak	 prior	 to	 frequency	 alignment	 to	 estimate	 the	 frequency	 offset	 in	 each	 of	 the	 four	subscans	of	our	MEGA-PRESS	acquisition.	Across	our	full	sample	of	42	subjects,	the	average	downfield	 frequency	 offset	 ranged	 from	 -.026	 ppm	 to	 +.050	 ppm	 (mean	 =	 +.0075	 ppm).	Similar	 to	 van	 der	 Veen	 et	 al.,	 we	 found	 that	 frequency	 offset	 was	 significantly	 and	positively	 correlated	 with	 LCModel	 fits	 for	 glutamate/creatine	 and	 glx/creatine	 in	 the	difference	 spectra	 (r	 =	 0.36,	 p	 =	 .02	 and	 r	 =	 0.62,	 p	 <	 .0001;	 respectively,	 both	 N	 =	 42)	(Figure	 2,	 panel	 F).	 Glx/creatine	 quantified	 by	 peak	 integration	 was	 similarly	 positively	correlated	with	frequency	offset	(r	=	0.60,	p	<	.0001,	N	=	42).	In	every	case,	the	frequency	offset	estimate	accounts	for	a	greater	proportion	of	the	variance	in	the	MP-Diff	values	than	is	accounted	for	by	the	PRESS	values.	Frequency	offset	did	not	correlate	significantly	with	glutamate	 or	 glx	 values	 from	 MP-Off	 or	 PRESS	 spectra,	 suggesting	 that	 the	 difference	spectra	were	 selectively	 vulnerable	 to	 this	 confounding	 effect	 (Supplemental	 Table).	We	then	used	partial	correlation	analysis	on	the	full	sample	to	see	if	controlling	for	the	effect	of	frequency	 offset	would	 improve	 the	 correlations	 between	MP-Diff	 and	 PRESS	 values	 for	glutamate	 and	 glx.	 Controlling	 for	 frequency	 offset	 led	 to	 either	 no	 change	 or	 modest	increases	 in	 these	 correlations,	 yielding	 r	 =	 0.22,	 r	 =	 0.33,	 and	 r	 =	 0.50	 for	 glutamate	by	LCModel,	glx	by	LCModel,	and	glx	by	peak	integration,	respectively	(all	N	=	42).	In	all	cases,	these	 partial	 correlations	 (controlled	 for	 frequency	 offset)	 were	 still	 significantly	 lower	than	 the	 corresponding	 correlations	 between	 PRESS	 and	 MP-Off	 values	 (Supplemental	Table).		
	By	 selectively	 influencing	 difference	 spectra	 values,	 frequency	 offset	 contributed	 to	 the	poor	correspondence	between	glutamate	and	glx	values	 from	PRESS	and	 those	 from	MP-difference	 spectra.	 However,	 controlling	 for	 frequency	 offset	 did	 not	 eliminate	 the	discrepancy	between	the	two	methods.	Thus,	additional	factors	must	also	contribute	to	this	poor	 correspondence.	 For	 example,	more	 transient	 frequency	offsets	 could	have	 affected	the	 difference	 spectra	 values,	 but	 would	 not	 have	 been	 detected	 by	 our	 method	 of	estimation	 from	 the	 3.6	 minute	 averaged	 subscans.	 In	 addition,	 non-linear	 effects	 of	frequency	offset	and	other	sources	of	instability	differentially	affecting	glutamate	signals	in	the	 difference	 spectra	 could	 also	 contribute	 to	 their	 poor	 correspondence	 with	 PRESS	values.		
4.3.	Possible	role	of	the	MEGA-PRESS	difference	spectrum	basis	set.	Bhogal	et	al.	(2017)	recently	reported	on	the	effects	of	different	processing	parameters	on	the	quantification	of	identical	7T	1H-MRS	scans.	In	their	study,	four	different	research	labs	analyzed	 the	 same	60	 scans	with	 LCModel	 software	using	 their	 preferred	 (but	 different)	processing	pipelines.	They	found	that,	unlike	NAA	fits,	glutamate	fits	showed	considerable	variation	between	processing	pipelines	(inter-lab	r	values	ranged	from	0.66	to	0.94).	The	authors	considered	 the	different	basis	 sets	used	by	each	 lab	 to	be	one	of	 the	parameters	responsible	for	the	varying	glutamate	values.	Other	potential	factors	identified	included	the	approach	to	modeling	the	baseline,	the	analysis	window,	and	prior	information	on	phasing.	For	various	reasons,	these	latter	parameters	seemed	unlikely	to	account	for	the	discrepant	results	 we	 observed	 with	 our	 difference	 spectra	 values.	 In	 difference	 spectra,	 baseline	
fluctuations	 are	 largely	 subtracted	 away.	 The	 analysis	 window	 used	 for	 the	 difference	spectra	 was	 explicitly	 prescribed	 by	 the	 LCModel	 manual.	 We	 used	 the	 same	 prior	information	on	phasing	 in	 the	analysis	of	 all	 of	 our	 spectra.	To	 test	 the	possibility	 that	 a	shortcoming	 in	 our	 basis	 set	 could	 account	 for	 the	 poor	 correlations	 observed	with	 the	difference	 spectra,	 we	 re-analyzed	 these	 spectra	 using	 the	 MEGA-PRESS	 difference	spectrum	basis	set	provided	by	LCModel.	This	is	a	widely-used	alternative	that	appears	to	incorporate	slightly	different	chemical	shift	and	coupling	values.	Results	of	this	re-analysis	supported	Bhogal	et	al.’s	observation	that	the	choice	of	basis	set	influences	the	glutamate	estimates.	The	correlation	between	 the	glutamate	values	estimated	by	 the	 two	basis	 sets	was	r	=	0.67,	suggesting	considerable	variability	is	introduced	by	the	basis	sets.	In	contrast,	the	glx	values	were	very	similar	 for	 the	 two	basis	sets	 (r	=	0.90).	 Importantly,	use	of	 the	alternative	basis	set	led	to	only	a	very	slight	improvement	in	the	correlation	between	the	PRESS	and	the	MP-Diff	glutamate	values	(r	=	0.35	vs.	r	=	0.32).	There	was	no	change	in	the	corresponding	correlation	for	the	glx	values	(r	=	0.27	for	both	basis	sets).	This	re-analysis	does	not	support	the	idea	that	the	poor	correlations	between	PRESS	and	MP-Diff	values	are	due	to	an	idiosyncratic	shortcoming	of	the	basis	set	used	for	the	difference	spectra.			It	 is	 possible	 that	 basis	 sets	 simulated	 from	more	 complete	modeling	 of	 the	 localization	pulses	 and	 of	 the	 frequency	 offset	 effects	 on	 the	 difference	 spectra	 could	 improve	 the	correspondence	 between	difference	 spectra	 and	PRESS	 spectra	 values	 for	 glutamate	 and	glx.	Many	widely	available	basis	 sets,	 including	all	basis	 sets	used	 in	 this	 study,	 treat	 the	localization	 pulses	 as	 hard	 pulses,	 and	 do	 not	 model	 the	 four-compartment	 effect	 or	imperfect	RF	profiles	 that	 reduce	 the	observable	 signal	 from	coupled	spins	 (Kaiser	et	al.,	
2008;	Mullins	et	al.,	2014).	These	effects	can	be	addressed	by	simulation	of	basis	sets	that	account	 for	 them	 or	 by	 use	 of	 acquisition	 parameters	 that	minimize	 them	 (Kaiser	 et	 al.,	2008).	 In	addition,	van	der	Veen	et	al.	 (2017)	have	recently	shown	that	basis	sets	can	be	tailored	 to	 account	 for	 the	 unique	 patterns	 of	 frequency	 offset	 occurring	 in	 individual	subjects.	 It	 is	 possible	 that	more	 precisely	 simulated	 basis	 sets	 or	 improved	 acquisition	parameters	would	have	reduced	the	discrepancy	we	observed	between	PRESS	and	MP-Diff	values	for	glutamate	and	glx.		
4.4	Interpreting	correlations	between	normalized	metabolite	values	from	the	same	
voxel.	It	 is	 worth	 noting	 that	 we	 have	 not	 reported	 the	 statistical	 significance	 (p	 values)	 of	correlations	between	pairs	of	glutamate	or	glx	measurements.	The	necessity	to	normalize	measured	metabolite	values	(typically	to	creatine	or	water)	creates	difficulties	in	assigning	significance	to	correlations	between	metabolites	from	the	same	voxel.	This	is	due	to	shared	variance	 in	 the	 denominators	 (e.g.	 creatine	 or	 water).	 In	 essence,	 the	 r	 value	 observed	when	 there	 is	 no	 true	 correlation	 between	 the	metabolite	 values	 in	 the	 numerator	 (null	hypothesis)	is	not	zero	but	some	unknown	positive	value	(	Maddock,	2014;	Pearson,	1897).	Across	 many	 studies	 in	 our	 lab,	 the	 median	 correlation	 among	 all	 pairs	 of	 well-fit	metabolites	measured	 in	 the	 same	 voxel	 and	 normalized	 to	 the	 same	 creatine	 value	 has	ranged	from	r	=	0.2	to	r	=	0.4.	This	may	serve	as	a	rough	estimate	of	the	expected	r	value	between	 creatine-normalized	metabolites	when	 there	 is	 no	 true	 correlation	between	 the	metabolites	 in	 the	numerators,	 as	may	be	 the	 case	 for	glutamate	measured	 in	 the	PRESS	and	 MP-Diff	 spectra	 here.	 However,	 assessing	 the	 statistical	 significance	 of	 differences	
between	 two	such	correlations	 is	 largely	 free	of	 this	problem	and	can	be	estimated	using	conventional	 methods	 (Maddock,	 2014).	 Thus,	 our	 conclusion	 that	 glutamate	 and	 glx	measurements	from	PRESS	spectra	correlated	more	strongly	with	the	same	measurements	from	 MEGA-PRESS	 off-resonance	 spectra	 than	 with	 those	 from	 MEGA-PRESS	 difference	spectra	is	not	compromised	by	the	use	of	creatine-normalized	metabolite	values.	
	
4.5	Limitations	Our	study	has	 limitations.	The	 individual	 transients	of	 the	MEGA-PRESS	acquisition	were	not	archived	for	post-processing.	Thus,	phase	and	frequency	alignment	was	performed	on	the	3.6	minute	subscans	rather	than	on	each	transient.	Alignment	of	 individual	transients	improves	the	quality	of	the	final	difference	spectra	used	for	quantification	of	metabolites.	This	limitation	in	our	processing	pipeline	may	have	contributed	to	the	poor	performance	of	the	difference	spectra	values	for	glutamate	and	glx.	However,	alignment	of	each	transient	during	post-processing	does	not	correct	for	the	changes	in	MEGA-PRESS	editing	efficiency	due	to	frequency	offset	during	acquisition	(van	der	Veen	et	al.,	2017).	In	addition,	we	used	a	single	set	of	conventional	scanning	parameters	(a	PRESS	sequence	with	TE	=	80	on	a	3T	system)	to	examine	correlations	with	MEGA-PRESS-derived	measures	of	glutamate	and	glx.	Replication	 in	 an	 independent	 sample	 using	 other	 scanning	 parameters	 for	 comparison	with	MEGA-PRESS	would	increase	confidence	in	the	generalizability	of	the	current	results.	In	 this	 regard,	 a	 recent	 re-examination	 of	 archival	 data	 showed	 a	 pattern	 similar	 to	 our	findings.	 On	 a	 4T	 system,	 Meyerhoff	 and	 colleagues	 (Mon	 et	 al.,	 2012)	 used	 a	 STEAM	sequence	 (TE	 =	 12	msec)	 to	measure	 glutamate	 and	 a	MEGA-PRESS	 sequence	 (TE	 =	 71	msec)	 to	measure	GABA	 and	 glx	 in	 three	 cortical	 voxels	 (anterior	 cingulate,	 dorsolateral	
prefrontal	 and	 parieto-occipital).	 In	 their	 combined	 sample	 of	 82	 subjects	 (recovering	alcoholics	 and	 age-matched	 controls),	 correlation	 coefficients	 between	 glutamate	 values	from	STEAM	and	glx	values	from	MEGA-PRESS	difference	spectra	of	the	same	voxels	from	the	 same	 subjects	 were	 low	 and	 similar	 to	 our	 findings	 (all	 r	 <	 0.23	 and	 all	 r2	 ≤	 0.05)	(Meyerhoff,	personal	communication).	Taken	 together,	 these	data	are	consistent	with	 the	view	 that	 glx	 measures	 derived	 from	 MEGA-PRESS	 difference	 spectra	 have	 little	correspondence	with	 conventional	 glutamate	measurements	 across	 different	 echo	 times,	acquisition	sequences	(PRESS	and	STEAM)	and	field	strengths	(3T	and	4T).	Further	studies	are	needed	to	ascertain	whether	our	finding	of	a	close	correspondence	between	glutamate	and	glx	values	derived	from	MEGA-PRESS	off-resonance	spectra	and	conventional	spectra	is	 similarly	 robust	 to	 differences	 in	 acquisition	 parameters.	 While	 many	 MEGA-PRESS	investigations	of	GABA	direct	the	off-resonance	editing	pulse	to	approximately	7.5	ppm	as	was	done	here	(Mullins	et	al.,	2014),	some	investigators	direct	the	off-resonance	pulse	to	1.5	 ppm	 in	 order	 to	 null	 co-editing	macromolecular	 resonances	 (Harris	 et	 al.,	 2015).	 An	editing	 pulse	 in	 this	 part	 of	 the	 spectrum	would	 not	 be	 expected	 to	 alter	 the	 glutamate	resonances	in	the	off-resonance	spectrum.	However,	the	current	data	cannot	address	how	well	 glutamate	 measures	 from	 the	 off-resonance	 spectra	 of	 this	 type	 of	 MEGA-PRESS	sequence	would	correlate	with	a	conventional	PRESS	acquisition.		
4.6	Conclusions	In	summary,	we	demonstrate	that	glutamate	and	glx	measurements	generated	from	the	off-resonance	spectra	of	a	GABA-optimized	MEGA-PRESS	sequence	are	highly	correlated	with	glutamate	 and	 glx	 measurements	 derived	 from	 a	 subsequently	 acquired	 conventional	
PRESS	scan.	In	contrast,	glutamate	and	glx	estimates	derived	from	the	difference	spectra	of	a	 GABA-optimized	 MEGA-PRESS	 sequence	 correspond	 poorly	 with	 such	 measurements	from	a	PRESS	scan.	For	many	experimental	questions,	it	may	be	advantageous	to	measure	glutamate	and	GABA	simultaneously	in	the	same	voxel	with	the	same	pulse	sequence.	Our	results	 support	 using	 glutamate	 estimates	 from	 the	 off-resonance	 spectra	 of	 a	 GABA-optimized	MEGA-PRESS	sequence	for	this	purpose.		
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Table	1:	Correlations	between	PRESS	and	two	MEGA-PRESS	measures	of	glutamate	 							
	 Controls	(n=25)	
	
							Patients	(n=17)	
	
						All	(n=42)	
	 r	(r2)	with	
PRESS		
CoV	
(%)	
r	(r2)	with	
PRESS		
CoV	
(%)	
r	(r2)	with	
PRESS		
CoV	
(%)	
	
PRESS		
	
---	 9.2	 ---	 8.2	 ---	 8.7	
	
MP-Off	
	
0.89	(0.79)	 8.2	 0.83	(0.69)	 6.1	 0.87	(0.75)	 7.3	
	
MP-Diff	
	
0.11	(0.01)**		 11.5	 0.42	(0.18)*		 9.7	 0.22	(0.05)**	 11.0	
CoV	=	coefficient	of	variation;	PRESS	=	PRESS	with	80	ms	TE;	MP-Off	=	MEGA-PRESS	off	resonance	
spectra;	MP-Diff	=	MEGA-PRESS	difference	spectra;	all	correlations	shown	are	between	
glutamate/creatine	ratios	from	LCModel	fits.	
**lower	than	PRESS	vs	MP-Off	correlation,	p	<	.0001	
*	lower	than	PRESS	vs	MP-Off	correlation,	p	<	.05	
	
Table	2:	Correlations	between	PRESS	and	three	MEGA-PRESS	measures	of	glx	
	 Controls	(n=25)	
	
							Patients	(n=17)	
	
						All	(n=42)	
	 r	(r2)	with	
PRESS		
CoV	
(%)	
r	(r2)	with	
PRESS		
CoV	
(%)	
r	(r2)	with	
PRESS		
CoV	
(%)	
	
PRESS	
	
---	 11.9	 ---	 9.8	 ---	 10.9	
	
MP-Off	
	
0.88	(0.77)	 9.2	 0.76	(0.58)	 8.9	 0.84	(.70)	 9.0	
	
MP-Diff	
	
0.16	(0.03)**	 10.1	 0.44	(0.20)
a
	 8.8	 0.26	(.07)**	 9.7	
	
MP-Diff-PI	
	
0.36	(0.13)**	 10.2	 0.49	(0.24)
a
	 11.0	 0.40	(.16)**	 11.0	
Abbreviations	as	in	Table	1;	MP-Diff-PI	=	MEGA-PRESS	difference	spectra	with	glx/creatine	quantified	by	
peak	integration,	all	others	are	glx/creatine	from	LCModel	fits.	Note	that	since	peak	integration	cannot	
estimate	glutamate	separately	from	glutamine,	peak	integration	values	are	only	shown	in	Table	2.	
**lower	than	PRESS	vs	MP-Off	correlation,	p	<	.0001	
*lower	than	PRESS	vs	MP-Off	correlation,	p	<	.05	
a
NS,	p	≤	.14	
Figure	legends	
Figure	1	–	Voxel	location	and	typical	spectra.		Panel	A	depicts	an	axial	slice	showing	the	dlPFC	voxel.	Panels	B,	C,	and	D	show	examples	of	PRESS,	MEGA-PRESS	off-resonance,	and	MEGA-PRESS	difference	spectra,	respectively.	For	B	through	D,	the	model	fit	(heavy	line)	is	superimposed	on	the	raw	spectral	data	(fine	line).	The	residual	(fit	minus	raw	data)	is	shown	at	the	top	of	each	panel.	Arrows	indicate	locations	of	visible	glutamate	resonances.	Note	that	glutamine	and	other	resonances	may	overlap	visually	with	glutamate	resonances.	Vertical	dashed	lines	in	D	indicate	the	ppm	range	used	for	peak	integration	of	the	glx	resonances	centered	at	3.74	ppm.	
	
Figure	2	-	Values	from	PRESS	versus	MEGA-PRESS	acquisitions.		Scatterplots	of	glutamate	estimated	from	PRESS	spectra	(PRESS	80)	versus	MEGA-PRESS	off-resonance	spectra	(MP-Off)	(panel	A);	glx	estimated	from	PRESS	80	versus	MP-OFF	(panel	B);	glutamate	estimated	from	PRESS	80	versus	MEGA-PRESS	difference	spectra	(MP-Diff)	(panel	C);	glx	estimated	from	PRESS	80	versus	MP-Diff	(panel	D);	and	glx	estimated	from	PRESS	80	versus	MP-Diff	by	peak	integration	(Peak	Int	MP-Diff)	(panel	E).	MP-Off	values	correlate	strongly	with	PRESS	80	values	but	MP-Diff	values	do	not.	Panel	F	illustrates	the	strong	relationship	between	MP-Diff	glx	values	and	downfield	frequency	offset	occurring	during	the	MEGA-PRESS	acquisition.	All	data	are	from	the	combined	sample	of	control	subjects	and	patients	(N=42),	with	closed	triangles	(
!
)	indicating	healthy	volunteers	and	open	circles	()	indicating	patients.		 	 	
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SUPPLEMENTS:	
Supplemental	Table	1:	Correlations	between	frequency	offset	during	MEGA-PRESS	acquisition	and	all	PRESS	and	MEGA-PRESS	measures	of	glutamate/creatine	and	glx/creatine	(N=42).		
	 Glutamate	 Glx	
	 r	(r2)	with	Freq	Offset	 r	(r2)	with	Freq	Offset	
	
PRESS		
	
0.04	(0.0)	 -0.01	(0.0)	
	
MP-Off	
	
0.22	(0.05)	 0.26	(0.07)	
	
MP-Diff	
	
0.36	(0.13)	 0.621	(0.39)	
	
MP-Diff-PI	
	
NA	 0.601	(0.36)	PRESS	=	PRESS	with	80	ms	TE;	MP-Off	=	MEGA-PRESS	off	resonance	spectra;	MP-Diff	=	MEGA-PRESS	difference	spectra;	MP-Diff-PI	=	MEGA-PRESS	difference	spectra	with	glx/creatine	quantified	by	peak	integration,	all	others	are	quantified	by		LCModel	fits.	1higher	than	correlations	without	a	superscript,	all	p	<	.05		Table	S1	shows	that	glx	measures	in	the	MP-Diff	spectra	were	significantly	more	strongly	correlated	with	frequency	offset	than	were	glutamate	measures	from	any	spectra	or	glx	measures	from	PRESS	or	MP-Off	spectra.					
Supplemental	Table	2:	Pairwise	correlations	among	all	glutamate/creatine	measures,	with	and	without	frequency	offset	controlled	by	partial	correlation	(N=42).		
Glutamate	
measures	
r	(r2)		
	
partial	r	(r2)	
(freq	offset)		
	
PRESS	vs	MP-Off	
	
0.87	(0.75)	 0.88	(0.78)	
	
PRESS	vs	MP-Diff	
	
0.22	(0.05)	 0.22	(0.05)	
	
MP-Off	vs	MP-Diff	
	
0.16	(0.02)	 0.08	(0.01)	All	abbreviations	as	in	Table	S1.		Table	S2	shows	that	controlling	for	frequency	offset	has	little	effect	on	the	pairwise	correlations	among	the	different	measures	of	glutamate.			 	
Supplemental	Table	3:	Pairwise	correlations	among	all	glx/creatine	measures,	with	and	without	frequency	offset	controlled	by	partial	correlation	(N=42).		
Glx	
measures	
r	(r2)		
	
partial	r	(r2)	
(freq	offset)		
	
PRESS	vs	MP-Off	
	
0.84	(.70)	 0.87	(0.75)	
	
PRESS	vs	MP-Diff	
	
0.26	(.07)	 0.33	(0.11)	
	
PRESS	vs	MP-Diff-PI	
	
0.40	(0.16)	 0.50	(0.25)	
	
MP-Off	vs	MP-Diff	
	
0.35	(0.12)	 0.25	(0.06)	
	
MP-Off	vs	MP-Diff-PI	
	
0.49	(0.24)	 0.44	(0.19)	
	
MP-Diff	vs	MP-Diff-PI	
	
0.76	(0.57)	 0.61	(0.38)	All	abbreviations	as	in	Table	S1.		Table	S3	shows	that	controlling	for	frequency	offset	during	the	MEGA-PRESS	acquisition	slightly	increases	correlations	between	the	MEGA-PRESS	measures	and	the	PRESS	measure	of	glx.	However,	pairwise	correlations	between	the	various	MEGA-PRESS	derived	measures	of	glx	are	reduced	when	controlling	for	frequency	offset	during	the	acquisition.				 	 	
Supplemental	Figure	Legend	The	figure	schematically	illustrates	the	excitation	profile	of	the	45	Hz	(0.335	ppm)	bandwidth	(FWHM)	Gaussian	on-resonance	editing	pulse	used	in	this	MEGA-PRESS	sequence	(red	tracing).	The	frequencies	of	the	coupling	partners	for	GABA	and	glutamate	are	also	illustrated	(blue	and	purple	dotted	lines).		Panel	A	shows	the	excitation	profile	when	the	pulse	is	centered	precisely	on	the	intended	GABA-editing	frequency	of	1.9	ppm	(no	frequency	offset).	Panel	B	shows	the	excitation	profile	when	the	center	frequency	of	the	editing	pulse	has	drifted	0.05	ppm	downfield	(the	maximum	averaged	downfield	offset	observed	in	our	dataset).	The	black	interval	line	above	the	glutamate	coupling	partner	illustrates	the	additional	excitation	of	the	glutamate	coupling	partner	with	this	degree	of	frequency	offset.	The	increased	excitation	of	glutamate	at	~2.08	ppm	is	expected	to	cause	increased	editing	efficiency	for	the	co-edited	glutamate	resonances	at	2.35	and	3.74	ppm.	A	similar	effect	will	occur	with	the	glutamine	coupling	partner	at	~	2.12	ppm	(not	shown).	We	observed	a	significant	positive	correlation	between	average	downfield	frequency	offset	and	co-edited	glutamate	and	glx	values	measured	in	the	MEGA-PRESS	difference	spectra	(see	Supplemental	Tables).				 	
SUPPLEMENTAL	FIGURE	
	
